Securities maintained its Neutral rating on Revance Therapeutics (NASDAQ:RVNC) with a steady price target of $3.65, closely ...
an unusual move after serving as president of Mizuho Securities Co., a group company. Sakai pushed a corporate downsizing agenda, which included cutting staff and integrating or closing bank ...
Yet "the bond market has not taken on board" the potential for 3% inflation in 2025, Steven Ricchiuto, chief economist at Mizuho Securities, wrote in a Monday client note. Even before December's ...
Geneos Wealth Management Inc. lessened its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 8.3% during ...
Qorvo (NASDAQ:QRVO) shares fell 0.5% in premarket trading on Friday, even as Mizuho Securities upped its earnings estimates on the involvement of activist investor Starboard Value. Mizuho analyst ...
Mizuho Financial Group, Inc. operates as a holding company which engages in the provision of financial services such as banking, trust banking, securities, and others. It operates through the ...
This year’s winners from Mizuho Americas were: Serena Lin, Managing Director and Head of Agency Mortgage-Backed Securities Trading Desk for Excellence in Fix NEW YORK, Aug. 28, 2024 (GLOBE ...
Mizuho Securities raised its recommendation on Vornado Realty Trust (NYSE:VNO) and Cousins Properties (NYSE:CUZ), and downgraded Kilroy Realty (NYSE:KRC), considering their geographic exposure and ...
Mizuho (NYSE:MFG) analysts maintained a Neutral rating on Revance Therapeutics (NASDAQ:RVNC), a $382 million market cap company, with a steady price target of $3.65. The firm's stance came in the wake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback